Current Radiopharmaceuticals

Sean L. Kitson
Current Radiopharmaceuticals
Almac Sciences
Almac House
20 Seagoe Industrial Estate
Craigavon, BT63 5QD
Northern Ireland


Targeted Alpha Therapy with 213Bi

Author(s): Alfred Morgenstern, Frank Bruchertseifer and Christos Apostolidis

Affiliation: European Commission, Joint Research Centre, Institute for Transuranium Elements, PO Box 2340, 76125 Karlsruhe, Germany.


The potential of targeted therapy with the alpha emitter 213Bi has been successfully demonstrated in a large number of preclinical studies and several clinical trials have provided evidence for its feasibility, safety and therapeutic efficacy. This review describes methods for the production of 225Ac and 225Ac/213Bi radionuclide generators, gives an overview of selected preclinical studies and summarizes the current clinical experience with 213Bi.

Keywords: Targeted alpha therapy, alpha emitter, actinium-225, bismuth-213, preclinical studies, clinical application, Alpha emitting radionuclides, RADIONUCLIDE GENERATORS, radiolabeled peptide, SPECT

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [295 - 305]
Pages: 11
DOI: 10.2174/1874471011104040295
Price: $58